Regulus Therapeutics shares surged 41% Tuesday in premarket trading after the company said it secured an oversubscribed $100 million equity financing.
Protara Therapeutics shares rallied 39%,.
Regulus Therapeutics reports findings for RGLS8429 in ADPKD study mechanistic dose response, encouraging biomarkers, and an oversubscribed $100M equity placement at $1.60 per share.
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 1% on Tuesday. The Dow traded up 0.48% to 38,955.84 while the NASDAQ rose 1.12% to 16,198.58. The S&P 500 also rose, gaining, 0.82% to 5,159.75.
Regulus Therapeutics Inc. announced positive topline results from the second cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. The Phase 1b MAD study is a.